Affinity Investment Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Affinity Investment Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-50,733	Closed	-$489K	–	191
2023 Q3	$489K	Hold	50,733	–	–	0.32%	122
2023 Q2	$540K	Sell	50,733 -11,161	-18%	-$120K	0.31%	125
2023 Q1	$651K	Hold	61,894	–	–	0.35%	115
2022 Q4	$767K	Buy	61,894 +478	+0.8%	+$5.42K	0.35%	105
2022 Q3	$636K	Hold	61,416	–	–	0.33%	110
2022 Q2	$708K	Sell	61,416 -2,490	-4%	-$29.3K	0.35%	100
2022 Q1	$804K	Sell	63,906 -2,460	-4%	-$28.2K	0.33%	110
2021 Q4	$774K	Buy	66,366 +358	+0.5%	+$4.39K	0.31%	120
2021 Q3	$862K	Buy	66,008 +31	+0%	+$401	0.39%	94
2021 Q2	$849K	Hold	65,977	–	–	0.38%	94
2021 Q1	$738K	Hold	65,977	–	–	0.27%	110
2020 Q4	$751K	Buy	+65,977	New	+$722K	0.3%	93

Other funds holding IRWD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Affinity Investment Advisors's IRWD Position: Q4 2023 in Review

Affinity Investment Advisors sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2023, closing a stake of 50,733 shares — an estimated $489K sold.

Affinity Investment Advisors first reported a position in IRWD in Q4 2020 and held it in 12 quarters. The position peaked at $862K in Q3 2021. 251 funds tracked by Wall St. Rank hold IRWD as of Q4 2023.

Affinity Investment Advisors reported no remaining Ironwood Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Affinity Investment Advisors sold 50,733 Ironwood Pharmaceuticals shares in Q4 2023, an estimated $489K.
Affinity Investment Advisors first reported a position in Ironwood Pharmaceuticals in Q4 2020 and held it in 12 quarters.
Affinity Investment Advisors's Ironwood Pharmaceuticals position peaked at $862K in Q3 2021.
251 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2023.

Based on Affinity Investment Advisors's 13F filing for Q4 2023, filed 9 Feb 2024.